Skip to main content

Table 3 Pooled relative risk of all grade and high grade irAEs for combination vs nivolumab

From: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

All grade irAEs No. of trials Pooled RR (95% CI) Pooled RR p Value High grade irAEs No. of trials Pooled RR (95% CI) Pooled RR p Value
Total incidence 2 1.067–1.254 1.157 0.000 Total incidence 2 1.337–2.089 1.672 0.000
Discontinuation 2 1.062–1.975 1.448 0.019 Discontinuation 1 1.133–2.656 1.735 0.011
Fatigue 2 0.550–1.660 0.956 0.872 Fatigue 2 0.720–11.245 2.845 0.136
Pruritis 2 1.320–2.736 1.900 0.001 Pruritis 2 0.245–91.337 4.731 0.304
Rash 2 0.508–2.391 1.102 0.806 Rash 2 0.491–4.239 1.442 0.506
Hyperthyroidism 2 0.947–13.480 3.573 0.060 Hyperthyroidism 1 0.188–111.215 4.577 0.350
Hypothyroidism 2 1.170–2.828 1.819 0.008 Hypothyroidism 1 0.124–14.921 1.358 0.803
Nausea 2 1.066–2.482 1.626 0.024 Nausea 2 0.323–12.855 2.037 0.449
Vomiting 2 0.877–3.123 1.655 0.120 Vomiting 2 0.232–10.670 1.573 0.643
Decreased appetite 1 1.282–3.064 1.982 0.002 Decreased appetite 1 0.246–91.812 4.156 0.302
Constipation 1 1.069–6.332 2.602 0.035 Constipation 1
Diarrhea 2 1.092–2.037 1.491 0.012 Diarrhea 2 0.514–5.392 1.664 0.396
Pneumomitis 1 0.353–5.161 1.351 0.660 Pneumomitis 1 0.217–18.948 2.026 0.536